2020
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O’Reilly R, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation 2020, 55: 2160-2169. PMID: 32390002, PMCID: PMC7606268, DOI: 10.1038/s41409-020-0926-1.Peer-Reviewed Original ResearchConceptsCAR T cellsAllo-HSCTT cellsCumulative incidenceCell transplantAllogeneic hematopoietic stem cell transplantAllogeneic hematopoietic cell transplantHematopoietic stem cell transplantCAR T-cell therapyConsolidative allo-HSCTHematopoietic cell transplantYoung adult patientsFavorable overall survivalStem cell transplantT-cell therapyFavorable OSOverall survivalAdult patientsSevere toxicitySmall cohortDisease controlPatientsCD34IncidenceRelapse
2014
Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute Leukemia
Mitchell R, Shah N, Lehrman R, Kobos R, Scaradavou A, Boulad F, Kernan N, O'Reilly R, Prockop S. Intrathecal Chemotherapy Post Hematopoietic Cell Transplantation for Prevention of Central Nervous System Relapse in Pediatric Acute Leukemia. Transplantation And Cellular Therapy 2014, 20: s84. DOI: 10.1016/j.bbmt.2013.12.104.Peer-Reviewed Original Research